MedTrace Logo

Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

NCT03073473 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2018-07-20

No results posted yet for this study

Summary

Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment. It, however, remains unclear if these new diagnostic technologies truly influence clinical and economic outcomes. This study will evaluate if patients treated according to the results of the NantHealth GPS Cancer test achieve optimal outcomes compared to patients whose treatment are discordant with GPS Cancer recommendations.

Conditions

Interventions

DIAGNOSTIC_TEST

NantHealth GPS Cancer Test

Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.

Sponsors & Collaborators

  • Blue Cross Blue Shield

    collaborator OTHER

  • NantHealth Inc.

    collaborator UNKNOWN

  • Cota Inc.

    lead INDUSTRY

Principal Investigators

  • Deena Atieh Graham, MD · Hackensack Meridian Health System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2018-06-13
Completion
2018-06-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03073473 on ClinicalTrials.gov